Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity was made in the provided transcript. The discussions focused on growth, new product launches, capex, margin improvement, and business strategy. Capex guidance mentioned is Rs. 150 Crores for the current year and slightly lower for next year, primarily for manufacturing and API facilities, but no details about raising funds for the same. There is no reference to any equity issuance or debt raising in the transcript. The company appears to be funding expansion and R&D from internal accruals or existing resources.

Any current/future capex/capital investment/strategic investment?

Capex guidance for current fiscal year is around Rs. 150 Crores. Next year's capex expected to be slightly lower but will depend heavily on the new API facility at Kolhapur. Overall planned capex of Rs. 250 to 300 Crores spread over 2-3 years. Major capex focus is on the new API facility at Kolhapur, being done in phases, which will be a key driver of future expenditures. Previous expansions at Goa and Pithampur API plant have been mostly completed, contributing to current expenses but less to future capex. The company is cautious on further capex dependent on market conditions and growth pros

Future growth expectations in sales/revenue/volumes?

Acute business in IPM is showing around 9.8% growth YTD and expected to continue similarly for next 3-4 quarters. Chronic segment growth is in double digits, with Unichem showing around 21% growth, almost double the market's 10%. Chronic growth seen as a consistent driver. US business growth has ranged between 20%-30% in past quarters with confidence to maintain that rate in near term. Unienzyme OTC brand showing early positive signs with about 10% growth after TV ad campaign; still early but expected to contribute more in coming quarters. Overall domestic business grew around 15%-16%,

Future growth expectations in earnings/operating earnings/profits/EPS?

Acute business in IPM showing ~9.8% YTD growth; similar trend expected for next 3-4 quarters; Unichem aims to match or outperform market in acute segment. Chronic segment growing robustly (~21.5% growth per AWACS); expected to continue double-digit growth, likely sustaining as consistent growth driver. US business has shown 20-30% growth in past quarters; management confident to maintain this rate for next few quarters. EBITDA margins expected to improve as turnover increases; current consolidated profits and margins already better than standalone. Margins targeted to improve by 150-20

Unichem LaboratoriesQ2 FY17Pharmaceuticals & Biotechnology

Unichem Laboratories Q2 FY17 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹498.75P/E: 29.5Market Cap: ₹3.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Acute business in IPM is showing around 9.8% growth YTD and expected to continue similarly for next 3-4 quarters.
Chronic segment growth is in double digits, with Unichem showing around 21% growth, almost double the market's 10%. Chronic growth seen as a consistent driver.
US business growth has ranged between 20%-30% in past quarters with confidence to maintain that rate in near term.
Unienzyme OTC brand showing early positive signs with about 10% growth after TV ad campaign; still early but expected to contribute more in coming quarters.
Overall domestic business grew around 15%-16%, combining volume growth (~9%) and price growth (~6%).
Company plans 6-8 ANDA filings over next year, with 2 product launches planned in US in current financial year.
Capex of Rs.150 Cr planned this year, focusing on API facilities to support growth.
Margin improvement anticipated as turnover grows and costs stabilize.

Margin guidance

Category 2

Acute business in IPM showing ~9.8% YTD growth; similar trend expected for next 3-4 quarters; Unichem aims to match or outperform market in acute segment.
Chronic segment growing robustly (~21.5% growth per AWACS); expected to continue double-digit growth, likely sustaining as consistent growth driver.
US business has shown 20-30% growth in past quarters; management confident to maintain this rate for next few quarters.
EBITDA margins expected to improve as turnover increases; current consolidated profits and margins already better than standalone.
Margins targeted to improve by 150-200 basis points on a year-on-year basis.
R&D and selling expenses rising due to new plants and US business expansion, but topline growth expected to outpace expense increases.
Capex planned around Rs. 150 Crores for current year; slightly lower next year but dependent on new API facility commissioning.
OTC segment (Unienzyme) showing early signs of growth; marketing expenses may increase based on results, supporting future earnings.

See what Unichem Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned fundraising through debt or equity was made in the provided transcript.
The discussions focused on growth, new product launches, capex, margin improvement, and business strategy.
Capex guidance mentioned is Rs. 150 Crores for the current year and slightly lower for next year, primarily for manufacturing and API facilities, but no details about raising funds for the same.
There is no reference to any equity issuance or debt raising in the transcript.
The company appears to be funding expansion and R&D from internal accruals or existing resources.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in precise terms. However, some related insights are: - US ANDA approvals pending: About six products approved but not yet launched. - The company is working towards launching around 6 to 8 ANDAs over the next year. - Around 15 pending ANDA filings with an estimated addressable market size of approximately 15-20 million (net of rebates and discounts). - The company is working on Para IV filings but specifics are confidential and still at R&D stage. - Capex planned around Rs. 150 Crores for the current year, primarily for API facility expansion at Kolhapur, which may suggest production capacity buildup to meet orders. - No specific order book size or pending orders value was disclosed.

See what Unichem Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex guidance for current fiscal year is around Rs. 150 Crores.
Next year's capex expected to be slightly lower but will depend heavily on the new API facility at Kolhapur.
Overall planned capex of Rs. 250 to 300 Crores spread over 2-3 years.
Major capex focus is on the new API facility at Kolhapur, being done in phases, which will be a key driver of future expenditures.
Previous expansions at Goa and Pithampur API plant have been mostly completed, contributing to current expenses but less to future capex.
The company is cautious on further capex dependent on market conditions and growth prospects.

Track Unichem Laboratories — get its next earnings analysis in your feed

How does Unichem Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisUnichem Laboratories

Rev 3Mar 2

See where Unichem Laboratories sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Unichem Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Unichem Laboratories against every Pharmaceuticals & Biotechnology company (Q2 FY17) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Unichem Laboratories's management said in earlier quarters

Earlier calls (3)

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →